1. mTOR Inhibition Increases Transcription Factor E3 (TFE3) Activity and Modulates Programmed Death-Ligand 1 (PD-L1) Expression in Translocation Renal Cell Carcinoma
- Author
-
Sungwoo Park, So Young Kim, Ji Sun Song, Mee Young Sol, Ju-Young Na, Jee Yeon Kim, Joon Young Park, Dong Hoon Shin, Hyun Jung Lee, Chung Su Hwang, and Jung Hee Lee
- Subjects
Regulation of gene expression ,Tumor microenvironment ,Gene knockdown ,Basic Helix-Loop-Helix Leucine Zipper Transcription Factors ,Chemistry ,TOR Serine-Threonine Kinases ,Chromosomal translocation ,TFE3 ,urologic and male genital diseases ,B7-H1 Antigen ,Kidney Neoplasms ,female genital diseases and pregnancy complications ,Pathology and Forensic Medicine ,Gene Expression Regulation, Neoplastic ,Cell Line, Tumor ,Gene expression ,Cancer research ,Humans ,Carcinoma, Renal Cell ,Transcription factor ,PI3K/AKT/mTOR pathway - Abstract
The efficacy of programmed death ligand (PD-L)-1/PD-1 checkpoint blockade in renal cell carcinoma (RCC) remains unknown. The effects of mTOR inhibitors are uncertain, and patients may develop resistance to them. The limited understanding of cancer cell-intrinsic mTOR-mediated pathways remains a challenge in developing effective treatments. Whether transcription factor (TF)-E3 regulates PD-L1 expression and the tumor microenvironment was investigated, and the effects of an mammalian target of rapamycin (mTOR) inhibitor on translocation RCC were explored. TFE3 was overexpressed in clear cell RCC cell lines, and PD-L1 expression was analyzed by Western blot analysis. PD-L1 activity in translocation RCC was analyzed in relation to TFE3 expression via TFE3 knockdown and treatment with an mTOR inhibitor. The results were correlated with the gene expression profile, evaluated using digital multiplex analysis. TFE3 and PD-L1 expression were positively correlated in RCC cells. TFE3 overexpression was associated with the expression of PD-L1 in RCC. Furthermore, mTOR inhibition was associated with enhanced PD-L1 expression via TFE3 activation in translocation RCC. These data support the feasibility of combination therapy based on mTOR inhibition and PD-L1 blockade as a novel strategy for the treatment of patients with translocation RCC.
- Published
- 2021